MediciNova

MediciNova is a biopharmaceutical company focused on developing small molecule therapeutics for the treatment of diseases. The company is focusing its development activities on MN-166 (ibudilast) for neurological disorders such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, and MN-001 (tipelukast) for fibrotic diseases such as nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis. The company's pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers.
  • TickerMNOV
  • ISINUS58468P2065
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
 PRESS RELEASE
MNOV MEDICINOVA (Health Care)

MediciNova to Present at the Ladenburg Thalmann 2021 Virtual Healthcar...

MediciNova to Present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference LA JOLLA, Calif., June 29, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Yuichi Iwaki, MD, PhD, President and Chief Executive Officer, and Geoffrey O'Brien, JD/MBA, Vice President and Executive Officer, will present a corporate overview at the Ladenburg Thalmann 2021 Virtual Healthcare Conference on Tuesday, July 13, 2021 at 4:30 pm ET. MediciN...

 PRESS RELEASE
MNOV MEDICINOVA (Health Care)

MediciNova Announces Positive Results from Phase 2 Trial of MN-166 (ib...

MediciNova Announces Positive Results from Phase 2 Trial of MN-166 (ibudilast) in Alcohol Use Disorder Published in Nature’s Translational Psychiatry Journal LA JOLLA, Calif., June 21, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that positive results from a Phase 2 trial of MN-166 (ibudilast) in alcohol use disorder (AUD) were published in Nature’s Translational Psychiatry. The clinical trial was a collaborative effort betwee...

 PRESS RELEASE
MNOV MEDICINOVA (Health Care)

MediciNova Initiates Sheep Study under Partnership with BARDA to Devel...

MediciNova Initiates Sheep Study under Partnership with BARDA to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury LA JOLLA, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has initiated a sheep study to investigate MN-166 (ibudilast) in an ovine model of chlorine-induced acute lung injury. Following treatment of the sheep with MN-166 (ibudilast) or control, the study...

 PRESS RELEASE
MNOV MEDICINOVA (Health Care)

MediciNova Reports First Quarter 2021 Financial Results and Business U...

MediciNova Reports First Quarter 2021 Financial Results and Business Update - Completed $20M private placement financing with 3D Investment Partners - - Entered into partnership with BARDA to evaluate MN-166 for chlorine gas-induced lung damage such as acute respiratory distress syndrome (ARDS) and acute lung injury (ALI) - - Received $4M in milestone payments from assignment agreement with Genzyme Corporation - - Strong cash balance of $76M to advance multiple late-stage programs - LA JOLLA, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., (Nasdaq: MNOV, JASDAQ:4875), a bio...

 PRESS RELEASE
MNOV MEDICINOVA (Health Care)

MediciNova Announces Partnership with BARDA to Develop MN-166 (ibudila...

MediciNova Announces Partnership with BARDA to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury LA JOLLA, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has partnered with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services...

 PRESS RELEASE
MNOV MEDICINOVA (Health Care)

MediciNova to Present at the Ladenburg Thalmann 2021 Virtual Healthcar...

MediciNova to Present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference LA JOLLA, Calif., June 29, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Yuichi Iwaki, MD, PhD, President and Chief Executive Officer, and Geoffrey O'Brien, JD/MBA, Vice President and Executive Officer, will present a corporate overview at the Ladenburg Thalmann 2021 Virtual Healthcare Conference on Tuesday, July 13, 2021 at 4:30 pm ET. MediciN...

 PRESS RELEASE
MNOV MEDICINOVA (Health Care)

MediciNova Announces Positive Results from Phase 2 Trial of MN-166 (ib...

MediciNova Announces Positive Results from Phase 2 Trial of MN-166 (ibudilast) in Alcohol Use Disorder Published in Nature’s Translational Psychiatry Journal LA JOLLA, Calif., June 21, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that positive results from a Phase 2 trial of MN-166 (ibudilast) in alcohol use disorder (AUD) were published in Nature’s Translational Psychiatry. The clinical trial was a collaborative effort betwee...

 PRESS RELEASE
MNOV MEDICINOVA (Health Care)

MediciNova Initiates Sheep Study under Partnership with BARDA to Devel...

MediciNova Initiates Sheep Study under Partnership with BARDA to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury LA JOLLA, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has initiated a sheep study to investigate MN-166 (ibudilast) in an ovine model of chlorine-induced acute lung injury. Following treatment of the sheep with MN-166 (ibudilast) or control, the study...

 PRESS RELEASE
MNOV MEDICINOVA (Health Care)

MediciNova Reports First Quarter 2021 Financial Results and Business U...

MediciNova Reports First Quarter 2021 Financial Results and Business Update - Completed $20M private placement financing with 3D Investment Partners - - Entered into partnership with BARDA to evaluate MN-166 for chlorine gas-induced lung damage such as acute respiratory distress syndrome (ARDS) and acute lung injury (ALI) - - Received $4M in milestone payments from assignment agreement with Genzyme Corporation - - Strong cash balance of $76M to advance multiple late-stage programs - LA JOLLA, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., (Nasdaq: MNOV, JASDAQ:4875), a bio...

 PRESS RELEASE
MNOV MEDICINOVA (Health Care)

MediciNova Announces Partnership with BARDA to Develop MN-166 (ibudila...

MediciNova Announces Partnership with BARDA to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury LA JOLLA, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has partnered with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services...

 PRESS RELEASE
MNOV MEDICINOVA (Health Care)

MediciNova to Present at the Ladenburg Thalmann 2021 Virtual Healthcar...

MediciNova to Present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference LA JOLLA, Calif., June 29, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Yuichi Iwaki, MD, PhD, President and Chief Executive Officer, and Geoffrey O'Brien, JD/MBA, Vice President and Executive Officer, will present a corporate overview at the Ladenburg Thalmann 2021 Virtual Healthcare Conference on Tuesday, July 13, 2021 at 4:30 pm ET. MediciN...

 PRESS RELEASE
MNOV MEDICINOVA (Health Care)

MediciNova Announces Positive Results from Phase 2 Trial of MN-166 (ib...

MediciNova Announces Positive Results from Phase 2 Trial of MN-166 (ibudilast) in Alcohol Use Disorder Published in Nature’s Translational Psychiatry Journal LA JOLLA, Calif., June 21, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that positive results from a Phase 2 trial of MN-166 (ibudilast) in alcohol use disorder (AUD) were published in Nature’s Translational Psychiatry. The clinical trial was a collaborative effort betwee...

 PRESS RELEASE
MNOV MEDICINOVA (Health Care)

MediciNova Initiates Sheep Study under Partnership with BARDA to Devel...

MediciNova Initiates Sheep Study under Partnership with BARDA to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury LA JOLLA, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has initiated a sheep study to investigate MN-166 (ibudilast) in an ovine model of chlorine-induced acute lung injury. Following treatment of the sheep with MN-166 (ibudilast) or control, the study...

 PRESS RELEASE
MNOV MEDICINOVA (Health Care)

MediciNova Reports First Quarter 2021 Financial Results and Business U...

MediciNova Reports First Quarter 2021 Financial Results and Business Update - Completed $20M private placement financing with 3D Investment Partners - - Entered into partnership with BARDA to evaluate MN-166 for chlorine gas-induced lung damage such as acute respiratory distress syndrome (ARDS) and acute lung injury (ALI) - - Received $4M in milestone payments from assignment agreement with Genzyme Corporation - - Strong cash balance of $76M to advance multiple late-stage programs - LA JOLLA, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., (Nasdaq: MNOV, JASDAQ:4875), a bio...

 PRESS RELEASE
MNOV MEDICINOVA (Health Care)

MediciNova Announces Partnership with BARDA to Develop MN-166 (ibudila...

MediciNova Announces Partnership with BARDA to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury LA JOLLA, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has partnered with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services...

 PRESS RELEASE
MNOV MEDICINOVA (Health Care)

MediciNova to Present at the Ladenburg Thalmann 2021 Virtual Healthcar...

MediciNova to Present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference LA JOLLA, Calif., June 29, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Yuichi Iwaki, MD, PhD, President and Chief Executive Officer, and Geoffrey O'Brien, JD/MBA, Vice President and Executive Officer, will present a corporate overview at the Ladenburg Thalmann 2021 Virtual Healthcare Conference on Tuesday, July 13, 2021 at 4:30 pm ET. MediciN...

 PRESS RELEASE
MNOV MEDICINOVA (Health Care)

MediciNova Announces Positive Results from Phase 2 Trial of MN-166 (ib...

MediciNova Announces Positive Results from Phase 2 Trial of MN-166 (ibudilast) in Alcohol Use Disorder Published in Nature’s Translational Psychiatry Journal LA JOLLA, Calif., June 21, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that positive results from a Phase 2 trial of MN-166 (ibudilast) in alcohol use disorder (AUD) were published in Nature’s Translational Psychiatry. The clinical trial was a collaborative effort betwee...

 PRESS RELEASE
MNOV MEDICINOVA (Health Care)

MediciNova Initiates Sheep Study under Partnership with BARDA to Devel...

MediciNova Initiates Sheep Study under Partnership with BARDA to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury LA JOLLA, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has initiated a sheep study to investigate MN-166 (ibudilast) in an ovine model of chlorine-induced acute lung injury. Following treatment of the sheep with MN-166 (ibudilast) or control, the study...

 PRESS RELEASE
MNOV MEDICINOVA (Health Care)

MediciNova Reports First Quarter 2021 Financial Results and Business U...

MediciNova Reports First Quarter 2021 Financial Results and Business Update - Completed $20M private placement financing with 3D Investment Partners - - Entered into partnership with BARDA to evaluate MN-166 for chlorine gas-induced lung damage such as acute respiratory distress syndrome (ARDS) and acute lung injury (ALI) - - Received $4M in milestone payments from assignment agreement with Genzyme Corporation - - Strong cash balance of $76M to advance multiple late-stage programs - LA JOLLA, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., (Nasdaq: MNOV, JASDAQ:4875), a bio...

 PRESS RELEASE
MNOV MEDICINOVA (Health Care)

MediciNova Announces Partnership with BARDA to Develop MN-166 (ibudila...

MediciNova Announces Partnership with BARDA to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury LA JOLLA, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has partnered with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services...

 PRESS RELEASE
MNOV MEDICINOVA (Health Care)

MediciNova to Present at the Ladenburg Thalmann 2021 Virtual Healthcar...

MediciNova to Present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference LA JOLLA, Calif., June 29, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Yuichi Iwaki, MD, PhD, President and Chief Executive Officer, and Geoffrey O'Brien, JD/MBA, Vice President and Executive Officer, will present a corporate overview at the Ladenburg Thalmann 2021 Virtual Healthcare Conference on Tuesday, July 13, 2021 at 4:30 pm ET. MediciN...

 PRESS RELEASE
MNOV MEDICINOVA (Health Care)

MediciNova Announces Positive Results from Phase 2 Trial of MN-166 (ib...

MediciNova Announces Positive Results from Phase 2 Trial of MN-166 (ibudilast) in Alcohol Use Disorder Published in Nature’s Translational Psychiatry Journal LA JOLLA, Calif., June 21, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that positive results from a Phase 2 trial of MN-166 (ibudilast) in alcohol use disorder (AUD) were published in Nature’s Translational Psychiatry. The clinical trial was a collaborative effort betwee...

 PRESS RELEASE
MNOV MEDICINOVA (Health Care)

MediciNova Initiates Sheep Study under Partnership with BARDA to Devel...

MediciNova Initiates Sheep Study under Partnership with BARDA to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury LA JOLLA, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has initiated a sheep study to investigate MN-166 (ibudilast) in an ovine model of chlorine-induced acute lung injury. Following treatment of the sheep with MN-166 (ibudilast) or control, the study...

 PRESS RELEASE
MNOV MEDICINOVA (Health Care)

MediciNova Reports First Quarter 2021 Financial Results and Business U...

MediciNova Reports First Quarter 2021 Financial Results and Business Update - Completed $20M private placement financing with 3D Investment Partners - - Entered into partnership with BARDA to evaluate MN-166 for chlorine gas-induced lung damage such as acute respiratory distress syndrome (ARDS) and acute lung injury (ALI) - - Received $4M in milestone payments from assignment agreement with Genzyme Corporation - - Strong cash balance of $76M to advance multiple late-stage programs - LA JOLLA, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., (Nasdaq: MNOV, JASDAQ:4875), a bio...

 PRESS RELEASE
MNOV MEDICINOVA (Health Care)

MediciNova Announces Partnership with BARDA to Develop MN-166 (ibudila...

MediciNova Announces Partnership with BARDA to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury LA JOLLA, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has partnered with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch